TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact 中文

Press Release


Jan, 2019

MabSpace Biosciences Merged with HJB to Form Transcenta Holding, a Fully Integrated Leading Global Biotherapeutics Company

HJB and MabSpace Biosciences (MabSpace) today announced that the two companies have entered into a definitive merger agreement to create Transcenta Holding Ltd., (Transcenta), a world-class biotherapeutics company with fully-integrated capabilities in research, development, regulatory and manufacturing of biologics. Dr. Xueming Qian, former Founder, Chairman and CEO of MabSpace, will serve as chief executive officer while Dr. Jonathan Yining Zhao, Co-founder and CEO of HJB, will be the Executive Chairman of the combined company, respectively.


Sep, 2018

MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA

(BUSINESS WIRE)--MabSpace Biosciences announced that on August 24th, 2018, MSB2311 was successfully administered to the first Chinese cancer patient at Beijing Cancer Hospital in its China Phase 1 trial.


Jul, 2018

HJB and 908 Devices Announce Joint Innovation Partnership

To Accelerate Biotherapeutics Analysis and Development in China by Bringing in ZipChip Platform
Dedicated to developing global antibody and recombinant protein biotherapeutics, HJB today announced a joint innovation partnership with 908 Devices, a pioneer of purpose-built analytical devices for chemical and biomolecular analysis.


Apr, 2018

MabSpace Initiated Global Phase 1 Trial of MSB2311, Its 2nd Generation PD-L1 Antibody With a Distinct Intra-Tumor Recycling Property

(BUSINESS WIRE)--MabSpace Biosciences announced today that the first subject has been dosed in a Phase 1 clinical study of MSB2311, for the treatment of advanced solid tumors.


Mar, 2018

HJB Establishes Clinical Development Team in Boston to Accelerate Global R&D and Filing.

HJB, an organization dedicated to expanding global access to important protein therapeutics, recently announced the establishment of its Center of Clinical Development (“the Center”) based in Boston.


Feb, 2018

MabSpace Biosciences Announces FDA Approval of IND for MSB2311, a Second Generation PD-L1 Antibody With pH Dependent Antigen Binding and Recycling Property

(BUSINESS WIRE)--MabSpace Biosciences announces on February 16th, 2018 FDA cleared Investigational New Drug (IND) for MSB2311, a humanized programmed death protein-ligand 1 (PD-L1) antibody for the treatment of patients with locally advanced/metastatic solid tumors.

1... 3 4 5 6 7